Quick Answer
Cadrenal Therapeutics, Inc. reported Stockholders Equity of $2.74 million for the year ending 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -63.2% in Stockholders Equity from 2024 to 2025.
- This data is from Cadrenal Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$169.1 thousand | Q2 2022: -$670.8 thousand | Q3 2022: -$1.18 million | Q1 2023: $4.07 million | Q2 2023: $3.18 million | Q3 2023: $8.75 million | Q1 2024: $6.19 million | Q2 2024: $3.99 million | Q3 2024: $3.41 million | Q1 2025: $6.11 million | Q2 2025: $4.30 million | Q3 2025: $2.73 million.
- Over the full 4 years of available data (2022 to 2025), Cadrenal Therapeutics, Inc.'s Stockholders Equity has grown by 149.3%.
- Historical annual values: Fiscal year 2025: $2.74 million | Fiscal year 2024: $7.44 million | Fiscal year 2023: $7.69 million | Fiscal year 2022: -$5.55 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: